Scynexis (SCYX) Other Non Operating Income (2014 - 2026)
Scynexis' (SCYX) quarterly Other Non Operating Income came in at $335000.0 in Q2 2026, down 5.37% quarter-over-quarter from $354000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Other Non Operating Income (2014 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Other Non Operating Income for 9 consecutive years, with $335000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non Operating Income changed N/A year-over-year to $335000.0; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 38.5% YoY), and the FY2025 full-year result was $750000.0, down 39.27% from the prior year.
- Other Non Operating Income declined to $335000.0 in Q2 2026 per SCYX's latest filing, from $354000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.0 million in Q4 2024 and bottomed at -$406000.0 in Q1 2023.
- Historically, Other Non Operating Income has averaged $338571.4 across 5 years, with a median of $189000.0 in 2022.
- The widest YoY moves for Other Non Operating Income: up 533.33% in 2023, down 141.43% in 2023.
- Over 5 years, Other Non Operating Income stood at $196000.0 in 2022, then surged by 375.51% to $932000.0 in 2023, then rose by 11.48% to $1.0 million in 2024, then declined by 27.82% to $750000.0 in 2025, then sank by 55.33% to $335000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $335000.0, $354000.0, and $750000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 335,000.00 |
| Mar 31, 2026 | 354,000.00 |
| Dec 31, 2025 | 750,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Dec 31, 2023 | 932,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | -406,000.00 |
| Dec 31, 2022 | 196,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Jun 30, 2022 | 182,000.00 |
| Mar 31, 2022 | 980,000.00 |
| Sep 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 462,000.00 |
| Mar 31, 2021 | -2.73 Mn |
| Dec 31, 2020 | 1.00 Mn |
| Sep 30, 2020 | 5.29 Mn |
| Jun 30, 2020 | -806,000.00 |